ArticleGenes, chromosomes & cancer2017

TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.

Sucheta Kulkarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.